替索单抗(Tisotumab Vedotin-tftv) - 药物靶点：Tubulin x tissue factor_在研适应症：转移性宫颈癌，复发性宫颈癌，宫颈癌_专利_临床

概要

基本信息

药物类型

ADC

别名

HuMax-TF、HuMax-TF-ADC、Humax TF ADC

+ [4]

靶点

Tubulin x tissue factor

作用方式

抑制剂

作用机制

微管蛋白抑制剂、tissue factor抑制剂(组织因子抑制剂)

治疗领域

肿瘤泌尿生殖系统疾病消化系统疾病+ [2]

在研适应症

转移性宫颈癌复发性宫颈癌宫颈癌+ [9]

非在研适应症

膀胱癌子宫内膜癌食管癌+ [6]

原研机构

Seagen, Inc.

在研机构

Genmab A/S湃朗瑞医药科技（北京）有限公司Genmab, Inc.

+ [5]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2021-09-20),

宫颈癌

最高研发阶段(中国)申请上市

特殊审评儿科研究计划 (美国)、优先审评 (美国)、加速批准 (美国)

登录后查看时间轴

结构/序列

分子式C39H67N5O7

InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N

CAS号474645-27-7

查看全部结构式(2)

使用我们的ADC技术数据为新药研发加速。

登录

或

查看完整样例数据

Sequence Code 319372688L

来源: *****

Sequence Code 319372616H

来源: *****

关联

18

项与替索单抗相关的临床试验

NCT05866354

/ Completed临床1期

An Open-Label, Phase 1 Trial to Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

The goal of this clinical trial is to test in Chinese Subjects with Metastatic or Recurrent Solid Malignancies. The main questions it aims to answer are:
How is the PK of tisotumab vedotin?
How is the immunogenicity of tisotumab vedotin?
How is the safety and tolerability of tisotumab vedotin?
How is the clinical efficacy of tisotumab vedotin? Participants will receive 2.0 mg/kg tisotumab vedotin (up to a maximum of 200 mg in subjects ≥ 100 kg) as a 30-minute IV infusion 1Q3W with the aim to characterize the PK profiles and to evaluate immunogenicity, safety, and tolerability of tisotumab vedotin in the Chinese population.
Subjects will receive study treatment until disease progression or any other discontinuation criteria are met, whichever occurs first. Subjects will undergo an end of treatment (EOT) visit 30 days (± 5 days) after the last dose of study treatment or within 7 days after treatment discontinuation has been decided, whichever occurs later.

开始日期2023-06-16

申办/合作机构

再鼎医药（上海）有限公司

CTR20231348

/ Completed临床1期

一项在复发或转移性的中国实体瘤受试者中评估Tisotumab Vedotin药代动力学的开放性Ⅰ期试验

主要：评估tisotumab vedotin的PK。次要：评估tisotumab vedotin的免疫原性。评估tisotumab vedotin的安全性和耐受性。探索性：评估tisotumab vedotin的临床疗效。

开始日期2023-06-06

申办/合作机构

再鼎医药（上海）有限公司

[+2]

CTR20223290

/ Active, not recruiting临床3期

一项在二线或三线复发性或转移性宫颈癌患者中比较 Tisotumab vedotin 与研究者所选化疗方案的随机、开放标签、III 期试验

主要目的：在 2L-3L 宫颈癌参与者中证明 Tisotumab vedotin 相较于化疗的临床疗效改善次要目的：1.在 2L-3L 宫颈癌参与者中评估 Tisotumab vedotin 相较于化疗的临床疗效改善 2.在 2L-3L 宫颈癌参与者中证明 Tisotumab vedotin 相较于化疗的抗肿瘤活性改善 3.在 2L-3L 宫颈癌参与者中表征 Tisotumab vedotin 和化疗的抗肿瘤应答 4.评估 Tisotumab vedotin 的安全性和耐受性 5.评估健康相关生活质量 (HRQOL) 6.评估 Tisotumab vedotin 的药代动力学 (PK) 和免疫原性

开始日期2023-02-09

申办/合作机构

湃朗瑞医药科技（北京）有限公司

100 项与替索单抗相关的临床结果

登录后查看更多信息

100 项与替索单抗相关的转化医学

登录后查看更多信息

100 项与替索单抗相关的专利（医药）

登录后查看更多信息

645

项与替索单抗相关的文献（医药）

2025-03-01·Annals of Emergency Medicine

Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know

Review

作者: Yeung, Sai-Ching J ; Merlin, Jeffrey ; Markides, Danna Michelle ; Hita, Angel Guido ; Reyes-Gibby, Cielto

Antibody-drug conjugates are novel antineoplastic agents whose use is expanding, both in terms of the number of drugs and the number of patients being treated. This article reviews the known toxicities and complications of antibody-drug conjugates that are currently approved for the treatment of cancer in the United States, with a focus on their emergency presentation and management. Similar to many other cancer therapies, most antibody-drug conjugates can cause diarrhea, nausea/vomiting, rash, peripheral neuropathy, and cytopenia, which are generally treated following standard-of-care. Interstitial lung disease, which may mimic pneumonia and cause respiratory failure and death, has been seen with trastuzumab deruxtecan and mirvetuximab soravtansine; emergency treatment of this condition includes oxygenation, ventilatory support, and corticosteroids. Inotuzumab ozogamicin and gemtuzumab ozogamicin are both associated with sinusoidal obstruction syndrome, a potentially fatal liver dysfunction that presents with weight gain, fluid overload, and jaundice. Abnormal liver function tests in patients who have been recently treated with these agents should be cautiously evaluated. Cardiac adverse events with antibody-drug conjugates are rare, but trastuzumab emtansine and trastuzumab deruxtecan may cause a decrease in cardiac contractility, and heart rate corrected QT interval prolongation is a rare effect of trastuzumab deruxtecan. Ocular adverse events, especially blurred vision, and keratopathy, are common with mirvetuximab soravtansine and tisotumab vedotin. Progressive multifocal leukoencephalopathy has been reported with brentuximab vedotin and polatuzumab vedotin. Tumor lysis syndrome may occur after treatment with gemtuzumab ozogamicin, polatuzumab vedotin, and brentuximab vedotin. Patients receiving enfortumab vedotin or brentuximab vedotin may develop hyperglycemia, sometimes presenting as diabetic ketoacidosis. Tisotumab vedotin and trastuzumab emtansine are associated with bleeding; although it is minor in most cases, severe bleeding and intracranial hemorrhage have occurred. Several antibody-drug conjugates can cause an anaphylactoid infusion-related reaction, which occurs most commonly during or soon after infusion but may be delayed up to 24 hours. Further research is needed to establish the real-world incidence of rare complications and how often patients with these complications present to the emergency department.

2025-02-03·Angewandte Chemie International Edition

Benzyl Ammonium Carbamates Undergo Two‐Step Linker Cleavage and Improve the Properties of Antibody Conjugates

Article

作者: Patel, Nimit L. ; Schnermann, Martin J. ; Kalen, Joseph ; Li, Xiaoyi

AbstractTargeted payload delivery strategies, such as antibody‐drug conjugates (ADCs), have emerged as important therapeutics. Although considerable efforts have been made in the areas of antibody engineering and labeling methodology, improving the overall physicochemical properties of the linker/payload combination remains an important challenge. Here we report an approach to create an intrinsically hydrophilic linker domain. We find that benzyl α‐ammonium carbamates (BACs) undergo tandem 1,6–1,2‐elimination to release secondary amines. Using a fluorogenic hemicyanine as a model payload component, we show that a zwitterionic BAC linker improves labeling efficiency and reduces antibody aggregation when compared to a commonly used para‐amino benzyl (PAB) linker as well as a cationic BAC. Cellular and in vivo fluorescence imaging studies demonstrate that the model payload is specifically released in antigen‐expressing cells and tumors. The therapeutic potential of the BAC linker strategy was assessed using an MMAE payload, a potent microtubule‐disrupting agent frequently used for ADC applications. The BAC‐MMAE combination enhances labeling efficiency and cellular toxicity when compared to the routinely used PAB‐Val‐Cit ADC analogue. Broadly, this strategy provides a general approach to mask payload hydrophobicity and improve the properties of targeted agents.

2025-02-01·Gynecologic Oncology Reports

Ocular surface disease related to tisotumab vedotin-tftv

Article

作者: Lent-Schochet, Daniella ; Paley, Grace L ; Farooq, Asim V ; Tauber, Shachar ; Seagrave, Zachary

IntroductionTo report a series of patients who developed ocular surface disease related to tisotumab vedotin-tftv (TV), an antibody-drug conjugate (ADC) approved for the treatment of recurrent or metastatic cervical cancer.MethodsThis was a multicenter retrospective chart review study of patients who developed ocular surface disease related to TV between April 1st, 2022 to August 31st, 2023.ResultsFive patients were identified who developed ocular surface disease while on TV. All patients received a standard ocular adverse event prophylaxis regimen with each infusion per the product label, including a cool ocular compress, topical vasoconstrictor, topical steroid, and artificial tears. All five patients developed conjunctival subepithelial fibrosis. Two patients developed bilateral pseudomembranous conjunctivitis, one of whom subsequently developed conjunctival scarring. Two patients developed a bilateral culture positive conjunctivitis, which responded to topical antibiotics. One patient developed bilateral infectious keratitis and was treated with partial thickness corneal transplantation of both eyes.ConclusionTV can be associated with ocular surface disease, including conjunctival scarring and infectious keratitis. Some cases may require surgical intervention. Oncologists and ophthalmologists should be aware of the possibility of these ocular complications, especially as more ADCs are approved. Further studies are required to determine toxicity mechanisms as well as optimal prophylaxis and management strategies.

281

项与替索单抗相关的新闻（医药）

2025-03-14

·SYNAPSE

2025年3月14日全球新药进展早知道

1. 再鼎ADC新药国内申报上市，治疗宫颈癌 3月13日，国家药品监督管理局（NMPA）药品审评中心（CDE）官网显示，再鼎医药与Seagen共同开发的维替索妥尤单抗的上市申请已获受理，用于治疗系统性治疗期间或之后病情进展的复发或转移性宫颈癌患者。维替索妥尤单抗是一款靶向组织因子（TF）的first in class抗体偶联药物（ADC），2024年4月，该药获得美国FDA完全批准，用于治疗在化疗期间或化疗后疾病进展的复发或转移性宫颈癌成年患者。2022年9月，再鼎医药从Seagen（在2023年被辉瑞收购）获得了在大中华区（中国内地、香港、澳门和台湾地区）开发和商业化维替索妥尤单抗的独家许可。 2. 首款国产实体瘤细胞疗法拟纳入优先审评 3月12日，CDE网站显示，永泰生物的T细胞疗法（Expanded Activated Lymphocytes，简称EAL）拟纳入优先审评，用于原发性肝细胞癌根治术后高复发风险的部分人群【免疫特性人群：患者需满足以下标准中的至少两项：无微血管侵犯；术后中性粒细胞和淋巴细胞比值（NLR）＜3；术后血小板和淋巴细胞比值（PLR）＜110】术后预防复发治疗。爱可仑赛属CIK细胞治疗产品，是由患者自体外周血中的单核细胞经使用专利方法活化、扩增培育而成的混合T淋巴细胞。2023年9月，爱可仑赛被纳入突破性治疗品种名单，用于预防原发性肝细胞癌根治性切除术后复发。永泰生物曾透露，根据其与CDE的沟通结果，后续可基于II期临床试验的中期结果或最终结果提交爱可仑赛用于预防肝癌术后复发的上市申请，前提为II期研究结果具有统计学意义。 3. 欧盟批准Rxulti用于青少年精神分裂症 3月13日，大冢制药（Otsuka Pharmaceutical）和灵北（Lundbeck）联合宣布，欧洲药品管理局批准Rxulti (brexpiprazole) 用于治疗 13 岁及以上青少年精神分裂症。该批准是在欧洲药品管理局人用药品委员会 (CHMP) 于 2025 年 1 月发布积极意见后做出的。欧盟委员会的批准是基于一项为期 6 周的随机、双盲、安慰剂对照和活性药物对照试验，该试验纳入了 316 名青少年患者。每日 2-4 毫克 brexpiprazole 的治疗显著降低了精神分裂症症状，以 PANSS 总分衡量，与安慰剂相比具有显著疗效。 4. 维持HIV病毒抑制48周，默沙东双药疗法达两项3期临床主要终点 3月12日，默沙东（MSD）宣布，在研每日一次口服双药方案doravirine/islatravir（DOR/ISL）在两项关键性3期试验中获得积极结果。在两项试验（MK-8591A-052和MK-8591A-051）中，DOR/ISL与活性对照组相比达到非劣效性标准。基于这些积极结果，默沙东计划在2025年中期启动向监管机构提交上市申请。 5. 康乐卫士三价HPV疫苗拟纳入优先审评 3月13日，CDE网站显示，康乐卫士的重组三价人乳头瘤病毒（16/18/58型）疫苗（三价HPV疫苗）拟纳入优先审评。该三价HPV疫苗为康乐卫士自主研发，主要用于预防HPV 16/18/58型相关的持续感染和宫颈癌等疾病。除全球主要高危型别HPV 16和18外，该三价HPV疫苗还覆盖了诱发东亚地区宫颈癌的第三大高危亚型HPV 58。相较于目前已上市的二价或四价HPV疫苗，该三价HPV疫苗将对东亚地区女性宫颈癌的保护范围从70%提高至78%。 1. 小野制药与Ionis达成超9亿美元合作，开发寡核苷酸疗法 3月12日，Ono Pharmaceutical（ONO）宣布已与Ionis Pharmaceuticals签订许可协议，获得反义寡核苷酸（ASO）疗法sapablursen的开发及商业化权益。Sapablursen是一种用于治疗真性红细胞增多症（PV）的在研ASO药物，目前正在2期临床试验IMPRSSION中针对成人PV患者进行评估。Sapablursen已于2024年1月获得美国FDA授予的快速通道资格，并于2024年8月获得孤儿药资格。根据协议，ONO将获得全球范围内开发和商业化sapablursen的独家许可。Ionis将继续负责完成正在进行的2期临床试验IMPRSSION，而ONO将全权负责后续开发、监管申报及商业化工作。ONO将支付2.8亿美元前期付款，并根据达到研发、监管及销售里程碑，支付高达6.6亿美元的额外里程碑付款。 2. 英矽智能完成1.1亿美元E轮融资 3月13日，英矽智能，一家由生成式人工智能驱动的生物医药科技公司，今日宣布已完成由亚洲最大的独立资产管理公司之一惠理集团（HKG: 0806）旗下的私募股权基金、浦东创投和浦发集团、锡创投和宜兴国控联合领投的1.1亿美元E轮融资。本轮融资还吸引了专注于行业和科技领域的新晋投资者的参与，并得到了现有投资者的支持。本轮融资所募得的资金将用于推动英矽智能在人工智能平台升级和药物研发管线创新方面的突破。

抗体药物偶联物优先审批疫苗融资

2025-03-13

·医药地理

再鼎医药宫颈癌治疗新药维替索妥尤单抗申报上市！

2025年3月13日，国家药品监督管理局（NMPA）药品审评中心（CDE）官网公布，再鼎医药与Seagen联合研发的维替索妥尤单抗（tisotumab vedotin）的上市申请已获受理，该药物主要用于治疗在系统性治疗期间或之后病情出现进展的复发或转移性宫颈癌患者。维替索妥尤单抗是一种靶向组织因子（TF）的First-in-class抗体偶联药物（ADC），通过蛋白酶可切割的连接子将微管破坏剂单甲基auristatin E（MMAE）与抗体共价连接。非临床研究显示，当ADC与肿瘤细胞表面TF结合后，通过受体介导的内吞作用进入胞内，经溶酶体蛋白酶水解后释放MMAE。该有效载荷可特异性干扰微管蛋白聚合，导致细胞周期停滞并诱导凋亡。体外实验证实，该药物同时具有抗体依赖性细胞吞噬（ADCP）和抗体依赖性细胞毒性（ADCC）效应。 2024年4月，该药物获得美国FDA完全批准，用于治疗在化疗期间或化疗后疾病进展的复发或转移性宫颈癌成年患者。2022年9月，再鼎医药从Seagen（2023年被辉瑞收购）获得了在大中华区（中国内地、香港、澳门和台湾地区）开发和商业化维替索妥尤单抗的独家许可。关键性III期临床试验innovaTV 301（NCT04697628）全球及中国亚组数据显示：在中国受试者中（n=53），维替索妥尤单抗较化疗显著降低45%死亡风险（HR=0.55，95%CI 0.27-1.15），其中半数以上患者既往接受过PD-(L)1抑制剂治疗。中位随访11.5个月时，治疗组中位总生存期（OS）尚未达到，对照组为10.7个月。次要终点方面，治疗组无进展生存期（PFS）和客观缓解率（ORR）亦显现显著优势。安全性分析显示中国亚组不良事件特征与全球数据一致，未发现新的安全性信号。 END 如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

抗体药物偶联物临床3期并购临床2期引进/卖出

2025-03-13

·医药笔记

再鼎医药：TF ADC递交上市申请

2025年3月13日，再鼎医药TF ADC新药维替索妥尤单抗的上市申请获得NMPA受理。今年1月，再鼎医药宣布维替索妥尤单抗治疗晚期宫颈癌的全球三期临床innovaTV 301研究中国亚组取得阳性主要结果。 Tivdak于2021年在美国获批上市，2024年销售额为1.3亿美元。 ADC为再鼎医药布局重点，除了TF ADC之外，DLL3 ADC、LRRC15 ADC、ROR1 ADC也在快速推进，其中DLL3 ADC将于今年启动小细胞肺癌关键临床。内容来源于网络，如有侵权，请联系删除。

抗体药物偶联物申请上市引进/卖出

100 项与替索单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	替索单抗	-	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
转移性宫颈癌	中国澳门	再鼎医药有限公司	2024-08-06
复发性宫颈癌	中国澳门	再鼎医药有限公司	2024-08-06
宫颈癌	美国	Seagen, Inc.	2021-09-20

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性宫颈癌	申请上市	美国	Genmab A/S	2024-01-09
转移性宫颈癌	申请上市	美国	Pfizer Inc.	2024-01-09
复发性宫颈癌	申请上市	美国	Genmab A/S	2024-01-09
复发性宫颈癌	申请上市	美国	Pfizer Inc.	2024-01-09
子宫颈转移癌	临床3期	中国	Genmab A/S	2021-02-22
子宫颈转移癌	临床3期	挪威	Genmab A/S	2021-02-22
子宫颈转移癌	临床3期	阿根廷	Genmab A/S	2021-02-22
子宫颈转移癌	临床3期	中国台湾	Genmab A/S	2021-02-22
子宫颈转移癌	临床3期	德国	Genmab A/S	2021-02-22
子宫颈转移癌	临床3期	捷克	Genmab A/S	2021-02-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04697628 (innovaTV 301, Company_Website) 人工标引	临床3期	宫颈癌	-	TIVDAK	(鹹鹹廠願鏇構糧鏇製觸) = 窪糧淵蓋積餘選憲艱鑰襯顧製獵膚壓艱簾遞獵 (積廠鹽壓製顧範餘簾蓋 )	积极	2025-01-15
				Chemotherapy	(鹹鹹廠願鏇構糧鏇製觸) = 憲鹽構齋鹽艱築築築鬱襯顧製獵膚壓艱簾遞獵 (積廠鹽壓製顧範餘簾蓋, 6.0 ~ NR)
NCT04697628 (innovaTV 301/ENGOT-cx12/GOG 3057 \| SGNTV-003 \| GOG-3057 \| innovaTV 301 \| ENGOT-cx12 \| innovaTV 301/ENGOT-cx12/GOG-3057, CTgov)	临床3期	子宫颈转移癌	502	tisotumab vedotin (Tisotumab Vedotin)	(蓋壓鹽網築醖繭淵鹽壓) = 艱艱醖醖鏇膚夢艱醖鏇艱選鏇艱選糧構築壓夢 (遞糧齋願廠衊廠廠廠壓, 鬱顧築顧獵遞鏇膚選糧 ~ 壓觸膚構鹽顧築獵製選) 更多	-	2024-08-09
				pemetrexed+vinorelbine+Gemcitabine+irinotecan+Topotecan (Chemotherapy)	(蓋壓鹽網築醖繭淵鹽壓) = 憲壓獵廠顧網夢願獵糧艱選鏇艱選糧構築壓夢 (遞糧齋願廠衊廠廠廠壓, 餘鏇糧齋選憲糧齋艱選 ~ 壓顧積顧衊鏇鏇餘鬱糧) 更多
NCT04697628 (innovaTV 301, Pubmed) 人工标引	临床3期	复发性宫颈癌二线 \| 三线	502	Tisotumab vedotin	(選窪顧願襯積鏇鹹膚鹽) = 壓醖顧鑰齋簾鹹繭餘艱簾築築膚醖獵遞鹹鑰憲 (鹹夢鏇襯構範簾製觸壓, 9.8 ~ 14.9) 更多	积极	2024-07-04
				Chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)	(選窪顧願襯積鏇鹹膚鹽) = 鏇糧襯選鑰鏇膚鏇壓夢簾築築膚醖獵遞鹹鑰憲 (鹹夢鏇襯構範簾製觸壓, 7.9 ~ 10.7) 更多
NCT03485209 (innovaTV 207, ASCO2024) 人工标引	临床2期	头颈部鳞状细胞癌	40	Tisotumab vedotin	(壓繭鬱鹹繭憲衊蓋壓獵) = 積壓憲鏇憲鬱簾網淵壓鹽鬱襯築窪夢壓蓋築壓 (鬱製鹹艱膚餘淵鬱積醖, 18.6 ~ 49.1) 更多	积极	2024-05-24
				Tisotumab vedotin (≤2 prior lines)	(壓繭鬱鹹繭憲衊蓋壓獵) = 窪齋獵鑰鑰選齋醖鏇廠鹽鬱襯築窪夢壓蓋築壓 (鬱製鹹艱膚餘淵鬱積醖, 21.1 ~ 61.3) 更多
NCT04697628 (ENGOT-cx12 \| GOG-3057 \| innovaTV 301, ASCO2024) 人工标引	临床3期	宫颈癌二线 \| 三线	502	Tisotumab vedotin (TV)	(鹹窪齋齋鏇壓選範壓鹹) = 網餘窪衊餘網積壓顧鹽遞築遞憲鑰醖繭蓋鹹膚 (艱築選願鹹襯襯膚網積, 13.3 ~ 23.1) 更多	积极	2024-05-24
				Chemotherapy	(鹹窪齋齋鏇壓選範壓鹹) = 遞網醖淵衊衊選蓋壓鑰遞築遞憲鑰醖繭蓋鹹膚 (艱築選願鹹襯襯膚網積, 2.8 ~ 8.8) 更多
NCT04697628 (innovaTV 301 \| ENGOT-Cx12 \| GOG-3057, ESGO2024) 人工标引	临床3期	宫颈癌二线 tissue factor	502	Tisotumab vedotin	(夢蓋鑰醖築製獵選鑰選) = 製夢壓餘鏇壓鹹膚蓋鬱遞餘窪積廠網窪鑰糧獵 (鬱積簾窪餘壓壓遞齋鹽, 9.8 ~ 14.9) 更多	积极	2024-03-10
				investigator’s choice of chemotherapy	(夢蓋鑰醖築製獵選鑰選) = 夢艱觸簾壓餘積衊廠糧遞餘窪積廠網窪鑰糧獵 (鬱積簾窪餘壓壓遞齋鹽, 7.9 ~ 10.7) 更多
NCT03786081 (innovaTV 205/GOG-3024/ENGOT-cx8, Pubmed \| J Clin Oncol)	临床1/2期	子宫颈转移癌一线 \| 三线 tissue factor	142	Tisotumab vedotin + Pembrolizumab	(糧餘廠醖鑰網壓網遞廠) = 鏇願餘繭壓觸膚獵製窪繭獵憲範窪願鬱壓願齋 (蓋鏇醖鬱襯構廠蓋醖壓, 23.7 ~ 59.4) 更多	积极	2023-12-20
				Tisotumab vedotin + Carboplatin	(糧餘廠醖鑰網壓網遞廠) = 糧觸鏇鹹鹽艱齋繭糧願繭獵憲範窪願鬱壓願齋 (蓋鏇醖鬱襯構廠蓋醖壓, 36.4 ~ 71.9) 更多
NCT04697628 (innovaTV 301 \| SGNTV-003 \| GOG-3057 \| ENGOT-cx12, ESMO 12023 \| ESMO 22023) 人工标引	临床3期	宫颈癌三线 \| 二线	502	Tisotumab vedotin	(選壓積遞選構夢淵窪鏇) = 鹽願鹽簾壓鬱壓遞窪製蓋糧窪選構遞鏇鑰壓製 (衊構夢觸壓鑰積觸夢夢, 9.8 ~ 14.9) 更多	积极	2023-10-22
				Investigator's choice of chemotherapy	(選壓積遞選構夢淵窪鏇) = 獵鬱選壓衊鑰構鹽醖廠蓋糧窪選構遞鏇鑰壓製 (衊構夢觸壓鑰積觸夢夢, 7.9 ~ 10.7) 更多
NCT04697628 (innovaTV 301, NEWS) 人工标引	临床3期	宫颈癌一线	-	Tivdak	(鑰鹹築觸衊選積願遞鬱) = 在一线治疗期间或治疗后疾病发生进展的复发性或转移性宫颈癌患者中，与单独化疗相比，接受其“first-in-class”抗体偶联药物（ADC）Tivdak（tisotumab vedotin）患者的OS显著改善範選鹽選膚願觸餘壓艱 (衊範顧範艱艱廠觸醖餘 ) 达到更多	积极	2023-09-06
				chemotherapy
NCT03657043 (CTgov)	临床2期	铂类耐药性原发性腹膜癌 \| 腹膜癌 \| 铂耐药性卵巢癌 \| 输卵管癌	98	3Q4W (Safety Run-In 0.9 mg/kg 3Q4W)	憲醖淵醖顧鹹網鹹淵構(鹹蓋蓋製齋網鬱淵積鑰) = 範壓範觸簾餘鹹醖範簾襯廠壓鬱齋遞範鏇簾憲 (積構齋鹽築範顧齋襯觸, 壓製築淵網範獵憲醖廠 ~ 糧夢夢鏇鹹壓顧膚築膚) 更多	-	2023-05-06
				3Q4W (Safety Run-In 1.2 mg/kg 3Q4W)	憲醖淵醖顧鹹網鹹淵構(鹹蓋蓋製齋網鬱淵積鑰) = 觸積觸餘願廠願製觸鹹襯廠壓鬱齋遞範鏇簾憲 (積構齋鹽築範顧齋襯觸, 蓋鑰製淵選壓獵選壓繭 ~ 窪選網積鏇遞鏇艱窪顧) 更多